Following in Banting’s footsteps or straying from the path? Observations from contemporary diabetes innovation

While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future.

Citation:
Leadley C, Addala A, Berkeley J, ……. Davis EA, Hewapathirana N, ……. Lomax K, Wilkinson T, et al. Following in Banting’s footsteps or straying from the path? Observations from contemporary diabetes innovation. Front Endocrinol. 2023;14

Keywords:
Diabetes technology; equity; type 1 diabetes; type 2 diabetes

Abstract:
While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future.